Viewing data from:

NADOLOL

ANDA

NADOLOL | A074172 | RISING PHARMA HOLDINGS INC

3 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Nadolol (2023)

Total Spending

$19.8M

Total Claims

260,861

Beneficiaries

65,690

Avg Cost/Unit

$0.94

Spending Trend

$39.5M(2019)→$35.9M(2020)→$24.8M(2021)→$23.6M(2022)→$19.8M(2023)

YoY Change:-15.5%

5yr CAGR:-16.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs1 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FERMION OYNADOLOL

DMF 62471986

SIGNA SA DE CVNADOLOL USP

DMF 74261988

MATRIX PHARMACORP PRIVATE LTDNADOLOL USP

DMF 249682011

BIOPHORE INDIA PHARMACEUTICALS PVT LTDNADOLOL

DMF 317352017

SYNCHEM CHEMICALS PRIVATE LTDInactiveNADOLOL

DMF 111921994

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 20MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Oct 31, 1993

No patent or exclusivity listings for this strength.

#002 — 40MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Oct 31, 1993

#003 — 80MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Oct 31, 1993